Pseudomonas Aeruginosa Infection

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Insmed
InsmedBRIDGEWATER, NJ
1 program
1
Liposomal amikacin for inhalationPhase 31 trial
Active Trials
NCT01315678Completed302Est. Sep 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
InsmedLiposomal amikacin for inhalation

Clinical Trials (1)

Total enrollment: 302 patients across 1 trials

NCT01315678InsmedLiposomal amikacin for inhalation

Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections

Start: Feb 2012Est. completion: Sep 2013302 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space